In 2014, the FDA and one year later, the European Medical Agency (EMA) approved pembrolizumab and nivolumab, both anti-PD-1 blocking antibodies, to treat advanced/unresectable melanoma in a second line, after the failure of ipilimumab or BRAF inhibitors (in case of BRAF mutation). Here, BRAF is linked to melanoma.